Acquired Companies

At Mallinckrodt Pharmaceuticals, we continually to look for companies that share our distinct values to help enhance and expand our diverse product portfolio. To see some of the companies we have acquired along the way, select from the growing list below


Sucampo Pharmaceuticals, Inc.

SEC Filings
SEC Filing Keyword Search (View search tips)
Year Filter 
Groupings Filter (View SEC Groupings descriptions)
View Section 16 Filings (3,4,5)
<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
02/23/1815-12BTermination of registration under Section 12(g) or suspension of duty to file reportsOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/15/18EFFECTEFFECTOther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/15/18EFFECTEFFECTOther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/15/18EFFECTEFFECTOther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/15/18EFFECTEFFECTOther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/15/18SC 13D/AAn amendment to a SC 13D filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/15/18SC 13D/AAn amendment to a SC 13D filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/14/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/14/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/13/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>
Governance Documents
Title
Download Documentation Audit Committee Charter
Download Documentation Compensation Committee Charter
Download Documentation Nominating and Corporate Governance Committee Charter
Download Documentation Corporate Governance Guidelines
Download Documentation Code of Conduct
Download Documentation Related Person Transaction Policy
Download Documentation Complaint Procedures Regarding Auditing and Accounting Matters
Download Documentation Code of Ethics for the Chief Executive Officer and Senior Financial Officers
Download Documentation Insider Trading Policy

Cadence Pharmaceuticals

(Acquired by Mallinckrodt Pharmaceuticals in 2014)
2012
Title
Download Documentation 2012 Annual Report
Download Documentation Proxy Statement
Download Documentation Proxy Card
2011
Title
Download Documentation 2011 Annual Report
Download Documentation Proxy Statement
Download Documentation Proxy Card
Get help downloading or viewing the above file types
SEC Filing Keyword Search (View search tips)
Year Filter 
Groupings Filter (View SEC Groupings descriptions)
View Section 16 Filings (3,4,5)
<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
04/14/14CT ORDERCT ORDEROther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
04/01/1415-12BTermination of registration under Section 12(g) or suspension of duty to file reportsOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
03/24/14SC 13D/AAn amendment to a SC 13D filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
03/21/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
03/21/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
03/21/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
03/21/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
03/21/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
03/21/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
03/21/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
02/28/14Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and twelve months ended December 31, 2013. Recent highlights included: Cadence entered into an agreement and plan of merger agreement with Mallinckrodt plc and one of its wholly owned indirect subsidiaries... 
Printer Friendly Version
02/11/14Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in Cash
February 11, 2014 Transaction accelerates growth in Mallinckrodt's Specialty Pharmaceuticals segment with addition of a high-growth, differentiated pain product Acquisition supports Mallinckrodt's expansion into the hospital channel Acquisition expected to be immediately accretive to Mallinckrodt's fiscal year 2014 adjusted diluted earnings per share; and significantly accretive to Mallinckrodt's fiscal year 2015 adjusted diluted earnings per sh... 
Printer Friendly Version
01/13/14Cadence Pharmaceuticals Estimates Fourth Quarter and Full Year 2013 Product Revenue and Provides Full Year 2014 Revenue Guidance
SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced preliminary (unaudited) estimates for net product revenues from sales of OFIRMEV® (acetaminophen) injection for the three months ended December 31, 2013, of approximately $33.3 million, and net product revenue for the twelve months ende... 
Printer Friendly Version
12/09/13New Data Detailing Economic Impact of IV Acetaminophen in Treating Acute Pain to be Presented at Two Major Healthcare Conferences
Presentations examine role of OFIRMEV® (acetaminophen) injection in improving outcomes and cost of care for treating acute pain associated with common joint replacement procedures ORLANDO, Fla., Dec. 9, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that results from a new study analyzing large-sc... 
Printer Friendly Version
11/26/13Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 4, 2013
SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO, Ted Schroeder, will present the company's corporate overview on Wednesday, December 4, 2013, at 11:30am Eastern Time (8:30am Pacific Time) during the 25th Annual Piper Jaffray Healthcare Conference ... 
Printer Friendly Version
11/14/13Cadence Pharmaceuticals Reports Positive Outcome In OFIRMEV® Patent Litigation
SAN DIEGO, Nov. 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the U.S. District Court for the District of Delaware has ruled in favor of Cadence in the company's patent infringement lawsuit against Exela Pharma Sciences, LLC. "We are very pleased with the Court's decision, as it confirms ou... 
Printer Friendly Version
11/08/13Cadence Pharmaceuticals Recognized As A Top Workplace In San Diego Based On Employee Feedback
Employee feedback through an anonymous survey included strong culture and employee engagement as top reasons to work for the companySAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today it has been recognized as one of U-T San Diego's Top Workplaces. The Top Workplaces are determined exclus... 
Printer Friendly Version
11/05/13Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2013. Highlights for the third quarter of 2013 included: Net product revenue for the third quarter of 2013 was $29.0 million, representing increases of $15.1 mil... 
Printer Friendly Version
10/29/13Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its third quarter ended September 30, 2013, financial results on Tuesday, November 5, 2013. Cadence management will host a conference call and live webcast to discuss the financial results on Tuesday, November 5, 20... 
Printer Friendly Version
09/04/13Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2013 On September 11, 2013
SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, September 11, 2013 at 3:50pm Eastern Time (12:50pm Pacific Time) during the Stifel Nicolaus Healthcare Conference 2013 at Four Seasons ... 
Printer Friendly Version
08/15/13Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
SAN DIEGO, Aug. 15, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Laureen DeBuono to the company's board of directors. Ms. DeBuono will also serve as a member of the company's audit committee."We are very pleased to welcome Ms. DeBuono to Cadence's board of directors," stated Cam G... 
Printer Friendly Version
08/15/13Cadence Pharmaceuticals Comments on USPTO's Non-Final, Initial Office Action on Reexamination of Patent
SAN DIEGO, Aug. 15, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that the United States Patent and Trademark Office (USPTO), has issued a non-final, initial office action in the Ex Parte Reexamination of US Patent No. 6,028,222, or the '222 patent, one of the two licensed patents covering OFIRMEV® (acetaminophen) injection. Although the USPTO made an initial determination to reject certain claims, all of the claims of the '222 patent remain valid and in force... 
Printer Friendly Version
08/06/13Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's Senior Vice President and Chief Commercial Officer Scott Byrd will present the company's corporate overview on Tuesday, August 13, 2013 at 12:45pm Eastern Time (9:45am Pacific Time) during the 2013 Wedbush PacGrow Life Sciences M... 
Printer Friendly Version
07/31/13Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
SAN DIEGO, July 31, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and six months ended June 30, 2013. For the second quarter ended June 30, 2013, Cadence reported net product revenue of $24.7 million, an increase of $13.6 million, or 123% from the second quarter of 2012,... 
Printer Friendly Version
07/24/13Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
SAN DIEGO, July 24, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its second quarter ended June 30, 2013, financial results on Wednesday, July 31, 2013. Cadence management will host a conference call and live webcast to discuss the financial results on Wednesday, July 31, 20... 
Printer Friendly Version
07/02/13Cadence Pharmaceuticals To Present At The 8th Annual JMP Securities Healthcare Conference On July 9, 2013
SAN DIEGO, July 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Tuesday, July 9, 2013 at 1:00pm Eastern Time (10:00am Pacific Time) during the 8th Annual JMP Securities Healthcare Conference at the St. Regis Hote... 
Printer Friendly Version
05/08/13Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013
SAN DIEGO, May 8, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's management will present a corporate overview at the following investment conferences during the month of May: Bank of America Merrill Lynch 2013 Health Care Conference at the Encore at the Wynn Hotel in Las Vegas on Wednesday, May... 
Printer Friendly Version
05/02/13Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2013. During the first quarter of 2013, Cadence reported net product revenue from sales of OFIRMEV® (acetaminophen) injection of $23.6 million, which includes the one-time recognition... 
Printer Friendly Version
04/25/13Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
SAN DIEGO, April 25, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its first quarter ended March 31, 2013 financial results on Thursday, May 2, 2013. Cadence management will host a conference call and live webcast to discuss the financial results on Thursday, May 2, 2013 at 1:30pm... 
Printer Friendly Version
03/14/13Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
SAN DIEGO, March 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Stephen L. Newman, M.D., to the company's board of directors."We are very pleased to welcome Dr. Newman to our board of directors. His experience in the evolving sector of integrated delivery networks, significant he... 
Printer Friendly Version
03/12/13Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National Formulary
SAN DIEGO, March 12, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), announced today that the Department of Veterans Affairs has made OFIRMEV® (acetaminophen) injection available on the VA National Formulary (VANF). The VANF is a list of products (drugs and supplies) generally covered under VA pharmacy benefits. VANF products must be available for prescription at all VA facilities. The purpose of the VANF management process is to provide high quality, best value pharmaceutical... 
Printer Friendly Version
03/07/13Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
-- 2012 Net Product Revenue Exceeds $50 Million -- SAN DIEGO, March 7, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the fourth quarter and full year ended December 31, 2012. For the fourth quarter of 2012, Cadence reported net product revenue from sales of OFIRMEV® (acetaminop... 
Printer Friendly Version
03/06/13Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection
SAN DIEGO, March 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags. Previously, Cadence announced the extension of it... 
Printer Friendly Version
02/28/13Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2012 financial results on Thursday, March 7, 2013. Cadence management will host a conference call and live webcast to discuss the financial results on Thursday, Ma... 
Printer Friendly Version
02/26/13Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEOTed Schroeder will present the company's corporate overview on Tuesday, March 5, 2013 at 11:20am Eastern Time (8:20am Pacific Time) during the Cowen & Company 33rd Annual Health Care Conference at th... 
Printer Friendly Version
02/06/13Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, February 13, 2013 at 3:30pm Eastern Time (12:30pm Pacific Time) during the Leerink Swann Global Healthcare Conference at the W... 
Printer Friendly Version
01/23/13Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a preliminary (unaudited) estimate of net product revenue from sales of OFIRMEV® (acetaminophen) injection for the three-months ended December 31, 2012, of approximately $17.1 million. "We ended 2012 on a high note, with fourth quarter ... 
Printer Friendly Version
12/12/12Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
SAN DIEGO, Calif., Dec. 12, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that it has entered into an agreement to terminate its exclusive option to acquire privately-held Incline Therapeutics, Inc., or Incline.Under the waiver, consent and option termination agreement signed by Cadence and Incline, u... 
Printer Friendly Version
11/28/12Cadence Pharmaceuticals Announces Settlement of OFIRMEV® (Acetaminophen) Injection Patent Litigation with Perrigo Company
SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it has entered into settlement and license agreements with Perrigo Company (Nasdaq: PRGO; TASE), and its subsidiary, Paddock Laboratories, LLC, to resolve pending patent litigation involving OFIRMEV® (acetaminophen) injection.The settlement agreement includes a stipulation by the parties requesting dismissal with prejudice of the lawsuit filed by Cadence in the U.S. District Court for the D... 
Printer Friendly Version
11/28/12Cadence Pharmaceuticals to Host Analyst and Investor Day
SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that the company will host an Analyst and Investor Day for financial analysts on Thursday, December 6, 2012, from 9:00 am to 12:00 pm EST in New York, NY. Members of the Cadence senior management team will provide an update on the OFIRM... 
Printer Friendly Version
11/21/12Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, November 28, 2012 at 10:30am Eastern Time (7:30am Pacific Time) during the Piper Jaffray 24th Annual Healthcare Conference at... 
Printer Friendly Version
11/05/12Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
SAN DIEGO, Nov. 5, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the third quarter and nine months ended September 30, 2012. Highlights from the third quarter include:Net product revenue for the third quarter of 2012 was $13.9 million, an increase of $2.8 million, or 25%, from $1... 
Printer Friendly Version
10/29/12Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
SAN DIEGO, Oct. 29, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its third quarter ended September 30, 2012 financial results on Monday, November 5, 2012. Cadence management will host a conference call and live webcast to discuss the financial results on Monday, November 5, 2012 ... 
Printer Friendly Version

Questcor Pharmaceuticals

(Acquired by Mallinckrodt Pharmaceuticals in 2014)
Title
Download Documentation Questcor Tax Basis Information
Download Documentation Form 10-K/A
Download Documentation Form 10-K
Get help downloading or viewing the above file types
SEC Filing Keyword Search (View search tips)
Year Filter 
Groupings Filter (View SEC Groupings descriptions)
View Section 16 Filings (3,4,5)
<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
08/25/1415-12BTermination of registration under Section 12(g) or suspension of duty to file reportsOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/20/148-KReport of unscheduled material events or corporate eventCurrent Reports Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/18/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/18/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/18/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/18/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/18/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/18/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/18/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/18/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
08/04/14Institutional Shareholder Services Inc. And Glass Lewis Recommend That Shareholders Of Mallinckrodt And Questcor Vote FOR Mallinckrodt's Acquisition Of Questcor
DUBLIN and ANAHEIM, Calif., Aug. 4, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt") and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) ("Questcor") today jointly announced that two leading independent proxy advisory firms, Institutional Shareholder Services Inc. (ISS) and Glass Lewis, have recommended a vote FOR the binding proposals relating to Mallinckrodt's acquisition of Questcor pursuant to the Agreement and Plan of Merger dated April 5, ... 
Printer Friendly Version
07/24/14Questcor Reports Record Second Quarter Financial Results
Net Sales $279 Million; Increase of 42% over Prior Year Non-GAAP Results GAAP EPS of $1.54, Non-GAAP EPS of $1.85 up 37% Year-Over-Year $99 Million of Operating Cash Flow Record 8,850 Acthar Vials Shipped in Quarter, up 26% over Prior Year Launched Commercial Effort in Lupus Expanding Pulmonology Sales Force Following Successful Pilot Effort ANAHEIM, Calif., July 24, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the second quarter... 
Printer Friendly Version
07/14/14Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction
--Registration Statement on Form S-4 Declared Effective by SEC-- --Record Dates for Mallinckrodt and Questcor Set for July 9, 2014-- --Companies Schedule Shareholder Meetings for August 14, 2014-- --Transaction Expected to be Completed in August 2014-- DUBLIN, IRELAND and ANAHEIM, CALIFORNIA - July 14, 2014 - Mallinckrodt plc (NYSE: MNK) and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange ... 
Printer Friendly Version
06/23/14Questcor Pharmaceuticals Closes Transaction to Acquire International Rights to Synacthen® and Synacthen® Depot
- Initiates Global Footprint, Diversifies Business, Enhances Long-term Growth Prospects - /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } ANAHEIM, Calif., June 23, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, ... 
Printer Friendly Version
06/03/14Questcor Provides Support to Lupus Foundation of America Awareness, Education and Advocacy Efforts
Company sponsors Walk to End Lupus Now™ events and employees show support for people with the disease during Lupus Awareness Month /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } HAYWARD, Calif., June 3, 2014 /P... 
Printer Friendly Version
05/28/14Questcor Receives "Recognition of Appreciation" Award from MS Views & News
HAYWARD, Calif., May 28, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has been honored with a "Recognition of Appreciation" Award from MS Views & News, Inc., a leading multiple sclerosis (MS) education, information and advocacy organization. "We are very proud to recognize Questcor for its exemplary support in helping to provide services to the multiple sclerosis community," said Stuart Schlossman, President and founder of MS Views & News. "... 
Printer Friendly Version
05/14/14Questcor Enters Into Development Collaboration Agreement Covering Novel Receptor-Selective Melanocortin Peptides
- Expands pipeline and broadens platform with next-generation melanocortin peptides - - Further enhances leadership position in melanocortin therapeutics - /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } ANAHEI... 
Printer Friendly Version
05/12/14Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Announce Early Termination of HSR Act Waiting Period
May 12, 2014 DUBLIN, Ireland & ANAHEIM, Calif.--(BUSINESS WIRE)-- Mallinckrodt plc (MNK), and Questcor Pharmaceuticals, Inc. (QCOR), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Mallinckrodt's proposed acquisition of Questcor, was terminated by the United States Federal Trade Commission on May 9, 2014. As previously announced on April 7, 2014, Mallinckrodt and Questcor entered i... 
Printer Friendly Version
05/05/14Cinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity in Patients with Systemic Lupus Erythematosus
- Significant clinical response to Acthar was observed in patients experiencing active disease while on conventional SLE maintenance therapies - - Findings supported by recent preclinical data demonstrating potential immunomodulatory activity and efficacy of Acthar in a mouse model of SLE - /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"... 
Printer Friendly Version
04/28/14Questcor Reports First Quarter Financial Results
- Net Sales $227 Million; Increase 68% Year-over-Year - - GAAP EPS of $1.20, Non-GAAP EPS of $1.40 up 84% - - $106M of Operating Cash Flow - - Rheumatology Largest Growth Contributor - - Mallinckrodt / Questcor Joint Merger Proxy Expected to be Filed in Mid-May - ANAHEIM, Calif., April 28, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the first quarter ended March 31, 2014. Three Months Ended 03/31/14 Three Months Ended 03/3... 
Printer Friendly Version
04/24/14Questcor to Report First Quarter Financial Results on April 28, 2014
ANAHEIM, Calif., April 24, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release first quarter 2014 financial results on Monday, April 28, 2014 after the close of the U.S. financial markets. In light of Questcor's pending merger with Mallinckrodt plc, the Company will not be hosting a conference call to discuss its financial results. Further details will be available in a Form 10-Q filing to be filed with the Securities and Exchange Commission af... 
Printer Friendly Version
04/21/14Clinical Trial Results Indicate Acthar May Significantly Reduce Proteinuria in Patients with Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
- Clinical results appear to correlate with reduction in anti-PLA2R antibodies /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } ANAHEIM, Calif., April 21, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasd... 
Printer Friendly Version
04/17/14Questcor Partners with National Kidney Foundation as National Sponsor of Kidney Walk
HAYWARD, Calif., April 17, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it is partnering with the National Kidney Foundation (NKF) to become a National Sponsor of Kidney Walk, the country's largest walk to raise money and awareness for kidney disease.Through this partnership, Questcor will support more than 85 Kidney Walks across the country. The nationwide series is comprised of community events that call attention to kidney disease and the need for o... 
Printer Friendly Version
04/07/14Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company
--Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Common Stock They Own-- --Combined Company Expected to Have Significantly Increased Scale, Revenues, Profitability and Cash Flow to Deliver Sustainable Growth Built on a More Diversified Product Platform of Novel Therapeutics-- --Transaction Expected to Be Immediately Accretive to Mallinckrodt's Fiscal Year 2014 Adjusted Diluted Earnings Per Share; Expected to Be Significantly Accretive to A... 
Printer Friendly Version
04/07/14Questcor Announces Quarterly Cash Dividend
ANAHEIM, Calif., April 7, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about July 8, 2014 to shareholders of record at the close of business on July 1, 2014. The Company previously announced the declaration of a quarterly cash dividend of $0.30 per share which will be paid on or about April 25, 2014 to s... 
Printer Friendly Version
03/20/14Questcor Contributes $175,000 to Endowment of Philip R. Dodge Young Investigator Award for Pediatric Neurology
- Company's total commitment to Endowment reaches $250,000 - /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } HAYWARD, Calif., March 20, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today an... 
Printer Friendly Version
02/25/14Questcor Reports Fourth Quarter and Full Year 2013 Financial Results
- Fourth Quarter Net Sales $243 Million; Increase 51% Year-over-Year - - Fourth Quarter GAAP EPS of $1.44, Non-GAAP EPS of $1.67 up 53% - - Full Year 2013 Net Sales $799 Million; Increase 57% Year-over-Year - - Full Year GAAP EPS of $4.76, Non-GAAP EPS of $5.48 up 65% - - Rheumatology Largest Growth Contributor - - Approximately One Million Shares Repurchased in Fourth Quarter - ANAHEIM, Calif., Feb. 25, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported fi... 
Printer Friendly Version
02/14/14Questcor Announces Quarterly Cash Dividend
ANAHEIM, Calif., Feb. 14, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about April 25, 2014 to shareholders of record at the close of business on April 18, 2014. About Questcor Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-... 
Printer Friendly Version
02/12/14Questcor to Report Fourth Quarter and Full Year 2013 Financial Results on February 25, 2014
ANAHEIM, Calif., Feb. 12, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release fourth quarter and full year 2013 financial results on Tuesday, February 25, 2014 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, February 25, 2014 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and corporate developments. The call can be accessed in the following ways:B... 
Printer Friendly Version
02/05/14Questcor Pharmaceuticals Expands Senior Management Team
ANAHEIM, Calif., Feb. 5, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the appointment of Rajesh (Raj) Asarpota as the Company's new Chief Financial Officer, effective February 17, 2014. Michael H. Mulroy, the Company's current CFO, will become Executive Vice President, Strategic Affairs and General Counsel, and spend increased time on the Company's recently announced initiative to investigate and evaluate potential strategic transactions to enhance sharehol... 
Printer Friendly Version
01/22/14Questcor Commits $500,000 to Launch of Questcor Research Fellowship Program for 2014
- Ten researchers awarded fellowship grants to further study in neurology, nephrology and rheumatology - HAYWARD, Calif., Jan. 22, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has funded independent researchers at 10 institutions for 2014. These investigators represent the first recipients of the newly-established Questcor Research Fellowship Program, which awards grants of $50,000 each to selected clinical and basic scientists to help fund thei... 
Printer Friendly Version
01/08/14Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
ANAHEIM, Calif., Jan. 8, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that Don Bailey, the Company's President and Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference in San Francisco on January 16, 2014 at 9:00 AM PT/12:00 PM ET. A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event. ... 
Printer Friendly Version
12/17/13Questcor Provides Donation In Support Of Children's Hospital & Research Center Oakland
HAYWARD, Calif., Dec. 17, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has made a $25,000 donation to the Children's Hospital & Research Center Oakland in support of the Early Intervention Services program.Children's Hospital & Research Center Oakland is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay that is 100% devoted to pediatrics. Their Early Intervention Services p... 
Printer Friendly Version
12/11/13Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program
ANAHEIM, Calif., Dec. 11, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about January 24, 2014 to shareholders of record at the close of business on January 17, 2014. The Company also announced today that it made open market purchases during the fourth quarter of 2013 of approximately 500,000 shares of ... 
Printer Friendly Version
12/09/13Questcor and Child Neurology Foundation Support the 5th Annual Infantile Spasms Awareness Week
- IS Hero Award goes to Dr. Carolina Amador and the staff at Lincoln Health Center, Corvallis, Oregon /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } HAYWARD, Calif., Dec. 9, 2013 /PRNewswire/ -- Questcor Pharm... 
Printer Friendly Version
12/05/13Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
ANAHEIM, Calif., Dec. 5, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Oppenheimer 24th Annual Healthcare Conference in New York City on December 11, 2013 at 8:20 AM ET/5:20 AM PT. A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event. About Questcor ... 
Printer Friendly Version
11/22/13Questcor Honored as an "Everyday Hero" by NephCure Foundation
-- Company recognized at NephCure annual "Countdown for a Cure" fundraiser /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:"0in"; } ANAHEIM, Calif., Nov. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NAS... 
Printer Friendly Version
11/12/13Questcor Adds G. Kelly Martin to Board of Directors
ANAHEIM, Calif., Nov. 12, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the addition of G. Kelly Martin, President and Chief Executive Officer of Elan Corporation, plc, to Questcor's Board of Directors, bringing the number of directors to eight, seven of whom are independent.Mr. Martin has served as Elan's President, Chief Executive Officer, and a member of its Board of Directors since February 2003. During Mr. Martin's tenure, he led a strategic plan to rest... 
Printer Friendly Version
11/07/13Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
ANAHEIM, Calif., Nov. 7, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the 2013 Credit Suisse Annual Healthcare Conference in Scottsdale, AZ on November 14, 2013 at 8:00 AM PT/11:00 AM ET. A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event. About Questcor ... 
Printer Friendly Version
10/29/13Questcor Reports Third Quarter Financial Results
- Net Sales and EPS Increase Over 65% Compared to Prior Year - - Vial Shipments up 45% Over Prior Year - - Record MS Prescriptions; Rheumatology Largest Growth Contributor - ANAHEIM, Calif., Oct. 29, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the third quarter and nine months ended September 30, 2013. Three Months Ended 09/30/13 Three Months Ended 09/30/12 Percentage ChangeNet Sales$236.3 Million$140.3 Million68%GAAP Dilu... 
Printer Friendly Version
10/22/13Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
ANAHEIM, Calif., Oct. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that it will commence a Phase 2 study to explore the efficacy and safety of H.P. Acthar® Gel (repository corticotropin injection) for Acute Respiratory Distress Syndrome (ARDS). The Company's Investigational New Drug (IND) application for the study has been reviewed by the U.S. Food and Drug Administration (FDA) and is now active. ARDS is an acute life-threatening lung condition that ca... 
Printer Friendly Version
10/10/13Questcor Increases Quarterly Cash Dividend 20 Percent
Dividend Increased to $1.20 per Share on an Annual Basis Second Dividend Increase in 2013 Reflects Growing Cash Flow /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:"0in"; } ANAHEIM, Calif., Oct. 10, 2013 /PRNewsw... 
Printer Friendly Version
10/08/13Questcor to Report Third Quarter Financial Results on October 29, 2013
ANAHEIM, Calif., Oct. 8, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release third quarter 2013 financial results on Tuesday, October 29, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, October 29, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments.. The call can be acc... 
Printer Friendly Version
09/05/13Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
ANAHEIM, Calif., Sept. 5, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will host investor meetings and will be a participant in a fireside chat session at the Morgan Stanley Global Healthcare Conference in New York City on September 10, 2013 at 4:40 PM ET/1:40 PM PT. The Conference does not accommodate formal presentations or the use of slides so there will not be a webcast presentation. About Questcor Questcor Pharmaceuticals... 
Printer Friendly Version
08/27/13Questcor Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
ANAHEIM, Calif., Aug. 27, 2013 /PRNewswire/ --Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Morgan Stanley Global Healthcare Conference in New York City on September 10, 2013 at 4:40 PM ET/1:40 PM PT. A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event. About Questcor ... 
Printer Friendly Version
07/30/13Questcor Reports Second Quarter Financial Results
- Net Sales and EPS Increase Significantly Over Prior Year - - Vial Shipments up 50% Over Prior Year - - Total Shipped Rxs up 35% YOY; Rheumatology Rxs Largest Growth Contributor - ANAHEIM, Calif., July 30, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the second quarter and six months ended June 30, 2013. Three Months Ended 06/30/13 Three Months Ended 06/30/12 Percentage ChangeGAAP Net Sales$184.6 Million$112.5 Million64%No... 
Printer Friendly Version
07/24/13Questcor to Commence Phase 2 Study of Acthar for ALS
ANAHEIM, Calif., July 24, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that patient screening will commence in connection with Questcor's Phase 2 Study to explore the safety and tolerability of H.P. Acthar® Gel (repository corticotropin injection) in patients with Amyotrophic Lateral Sclerosis (ALS). ALS -- often referred to as Lou Gehrig's disease -- is a progressive, degenerative disease affecting motor neurons. ALS is a serious debilitating disease that... 
Printer Friendly Version
07/12/13Questcor to Report Second Quarter Financial Results on July 30, 2013
ANAHEIM, Calif., July 12, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release second quarter 2013 financial results on Tuesday, July 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, July 30, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments.. The call can be access... 
Printer Friendly Version
07/11/13Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
ANAHEIM, Calif., July 11, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced its intent to initiate a pilot commercialization effort for H.P. Acthar® Gel (repository corticotropin injection) for the treatment of respiratory manifestations of symptomatic sarcoidosis, a potentially serious, difficult-to-treat disorder already included on the FDA-approved package insert for Acthar. The pilot effort will focus on pulmonologists, who are the respiratory specialists tr... 
Printer Friendly Version
06/11/13Questcor Pharmaceuticals Acquires Rights to Synacthen®
- Expands Questcor's Presence in Inflammatory and Autoimmune Disorders - - Provides Foundation for Next Generation Melanocortin Receptor Agonist Therapeutics - - Initiates Global Footprint, Diversifies Business, Enhances Long-term Growth Prospects - /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_... 
Printer Friendly Version
06/10/13Questcor Adds Angus C. Russell to Board of Directors
ANAHEIM, Calif., June 10, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the addition of Angus C. Russell, recently-retired Chief Executive Officer of Shire plc, to Questcor's Board of Directors. Shire is a global specialty biopharmaceutical company whose 2012 revenues exceeded $4.6 billion. During Mr. Russell's five-year tenure as Chief Executive Officer, Shire introduced several new products, grew revenues over 50%, and increased earnings approximately fiv... 
Printer Friendly Version
05/29/13Questcor Pharmaceuticals Announces Quarterly Dividend
ANAHEIM, Calif., May 29, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that its Board of Directors has declared a quarterly cash dividend of $0.25 per share to shareholders of record at the close of business on July 22, 2013. The dividend is scheduled to be paid on or about July 30, 2013. About Questcor Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inf... 
Printer Friendly Version
05/08/13Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
ANAHEIM, Calif., May 8, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas on May 14, 2013 at 4:20 PM PT/7:20 PM ET. A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event. About Questcor ... 
Printer Friendly Version
04/30/13Questcor Reports First Quarter Financial Results
- Net Sales Increase 41% Year Over Year; Down Sequentially - - April Vial Shipments Rebound Significantly Establishing a New Monthly Record- - Prescription Levels in Rheumatology Increasing - - Phase 2 Clinical Trial of Acthar in ALS to Start under FDA Accepted IND - ANAHEIM, Calif., April 30, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the first quarter ended March 31, 2013. Financial results include BioVectra Inc. since January 18... 
Printer Friendly Version
04/15/13Questcor to Report First Quarter Results on April 30, 2013
ANAHEIM, Calif., April 15, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release first quarter 2013 financial results on Tuesday, April 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, April 30, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments.The call can be access... 
Printer Friendly Version
02/26/13Questcor Reports Fourth Quarter and Full Year 2012 Results
- Net Sales, EPS and Cash Flow from Operations Increase Significantly Over Prior Year Period - - Continues to Expand R&D Efforts - - Increases Quarterly Dividend 25% to $0.25 per share - ANAHEIM, Calif., Feb. 26, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2012. Three Months Ended 12/31/12Three Months Ended 12/31/11Percentage ChangeNet Sales$160.5 Million$75.5 Million113%G... 
Printer Friendly Version
02/06/13Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
ANAHEIM, Calif., Feb. 6, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release fourth quarter and full year 2012 financial results on Tuesday, February 26, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, February 26, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter and full year, as well as current corporate de... 
Printer Friendly Version
01/28/13Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
ANAHEIM, Calif., Jan. 28, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the appointment of Michael Aldridge to the new position of Senior Vice President, Corporate Strategic Development. Mr. Aldridge's primary responsibilities will be the identification and development of partnership and acquisition opportunities to leverage Questcor's business model. Over time, such initiatives may include development programs or products complementary to Acthar (H.P. Acth... 
Printer Friendly Version
01/03/13Questcor Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
ANAHEIM, Calif., Jan. 3, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 10, 2013 at 9:00 a.m. PT / 12:00 p.m. ET. A live webcast with accompanying slide presentation, and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available f... 
Printer Friendly Version
01/02/13Questcor Pharmaceuticals to Acquire BioVectra Inc.
-- Transaction provides vertical integration, third party manufacturing capabilities and further secures Acthar manufacturing trade secrets -- -- Acquisition expected to be accretive to future financial results -- /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt; font-fami... 
Printer Friendly Version
12/04/12Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
ANAHEIM, Calif., Dec. 4, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share to all shareholders of record at the close of business on December 14, 2012. The dividend will be paid in lieu of the Company's regular quarterly cash dividend that would have been paid in the first quarter of 2013, and is scheduled to be paid on or about December 21, 2012. The Company accelerated paymen... 
Printer Friendly Version
12/03/12Questcor Teams With Child Neurology Foundation To Continue Funding Infantile Spasms Scientific Research
- CNF Names Dr. Alex R. Paciorkowski of the University of Rochester Medical Center as 2012 Recipient of CNF's Infantile Spasms Research Award /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt; font-family:"Arial"; color:black; } HAYWARD, Calif., Dec. 3, 2012 /PRNewswi... 
Printer Friendly Version
12/03/12Questcor and Child Neurology Foundation Support the 4th Annual Infantile Spasms Awareness Week
- Infantile Spasms Hero Award goes to Dr. Ali Mostajelean and Children's Hospital & Research Center of Oakland /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt; font-family:"Arial"; color:black; } HAYWARD, Calif., Dec. 3, 2012 /PRNewswire/ -- Questcor Pharmac... 
Printer Friendly Version
10/23/12Questcor Reports Third Quarter Financial Results
ANAHEIM, Calif., Oct. 23, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the third quarter and nine months ended September 30, 2012. Three Months Ended 9/30/12Three Months Ended 9/30/11Percentage ChangeNet Sales$140.3 Million$59.8 Million135%GAAP Diluted EPS$0.91$0.35160%Non-GAAP Diluted EPS$0.97$0.37162% Nine months Ended 9/30/12Nine months Ended 9/30/11Percentage ChangeNet Sales$348.8 Million$142.6 Million145%GAAP Diluted EPS$2.1... 
Printer Friendly Version
10/15/12Questcor to Report Third Quarter Results on October 23, 2012
ANAHEIM, Calif., Oct. 15, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release third quarter 2012 financial results on Tuesday, October 23, 2012 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, October 23, 2012 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments. The call can be ac... 
Printer Friendly Version
09/28/12Questcor Pharmaceuticals Initiates Quarterly Cash Dividend and Expands Stock Repurchase Program
ANAHEIM, Calif., Sept. 28, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that its Board of Directors has adopted a policy to pay a regular quarterly dividend in such amounts as the Board of Directors may determine from time to time. The Board of Directors has declared an initial quarterly cash dividend of $0.20 per share to all shareholders of record at the close of business on October 31, 2012. The initial dividend will be paid on or about November 15, 201... 
Printer Friendly Version
09/19/12Questcor Comments on Insurance Policy Bulletin
ANAHEIM, Calif., Sept.19, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today commented on information regarding an insurance policy bulletin issued with respect to the Company's primary product H.P. Acthar® Gel (repository corticotropin injection) ("Acthar").The Company is continuing to review the Clinical Policy Bulletin related to Acthar from Aetna Inc. ("Aetna"). Currently, the Company does not believe that the bulletin represents a material change in insurance coverage... 
Printer Friendly Version
09/19/12Questcor to Conduct Conference Call to Discuss Reimbursement Process
ANAHEIM, Calif., Sept. 19, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will conduct a conference call to discuss the reimbursement process for H.P. Acthar Gel (repository corticotrophin injection) prescriptions. The call will take place on Thursday, September 20, 2012 at 11 a.m. ET, 8 a.m. PT. The call can be accessed in the following ways:By webcast: At Questcor's investor relations website: http://ir.questcor.com/. By telephone: For both "listen-... 
Printer Friendly Version
09/13/12Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
ANAHEIM, Calif., Sept. 13, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the company will be teaming up with The Myositis Association (TMA) to support research and educational initiatives in dermatomyositis and polymyositis."Questcor is very pleased to be able to make this commitment to The Myositis Association and the dermatomyositis and polymyositis communities," said Steve Cartt, Chief Operating Officer of Questcor. "Further research into these rare a... 
Printer Friendly Version
09/05/12Questcor Pharmaceuticals to Present at Investor Conferences in September
ANAHEIM, Calif., Sept. 5, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the following investor conferences in September 2012:Morgan Stanley Global Healthcare Conference in New York City on September 11, 2012 at 3:30 PM ET. G9: ThinkEquity's 9th Annual Growth Conference in New York City on September 12, 2012 at 3:30 PM ET. A live webcast and subsequent archived replay of the presentations will be accessible at http://... 
Printer Friendly Version
Print Page Print Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts